Giuseppe Lombardi1, Ardi Pambuku2, Luisa Bellu2, Miriam Farina3, Alessandro Della Puppa4, Luca Denaro5, Vittorina Zagonel2. 1. Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy. Electronic address: giuseppe.lombardi@ioveneto.it. 2. Department of Clinical and Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy. 3. Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology, IOV - IRCCS, Padua, Italy. 4. Neurosurgery Department, Azienda Ospedaliera di Padova, Padua, Italy. 5. Neurosurgery Department, University of Padua, Padua, Italy.
Abstract
BACKGROUND: glioblastomas are highly vascularized tumors and various antiangiogenic drugs have been investigated in clinical trials showing unclear results. We performed a systematic review and a meta-analysis to clarify and evaluate their effectiveness in glioblastoma patients. PATIENTS AND METHODS: we searched relevant published and unpublished randomized clinical trials analyzing antiangiogenic drugs versus chemotherapy in glioblastoma patients from January 2006 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases. RESULTS: fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR=1.24, p=0.056). Bevacizumab did not improve overall survival. Twelve trials (4113 patients) were analyzed for progression-free survival. Among antiangiogenic drugs, only bevacizumab demonstrated an improvement of progression-free survival (HR=0.63, p<0.001), both alone (HR=0.60, p=0.003) or in combination to chemotherapy (HR=0.63; p<0.001), both as first-line treatment (HR=0.70, p<0.001) or in recurrent disease (HR=0.52, p<0.001). CONCLUSIONS: antiangiogenic drugs did not improve overall survival in glioblastoma patients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy. Among antiangiogenic drugs, only bevacizumab improved progression-free survival regardless of treatment line, both as single agent or in combination with chemotherapy.
BACKGROUND:glioblastomas are highly vascularized tumors and various antiangiogenic drugs have been investigated in clinical trials showing unclear results. We performed a systematic review and a meta-analysis to clarify and evaluate their effectiveness in glioblastomapatients. PATIENTS AND METHODS: we searched relevant published and unpublished randomized clinical trials analyzing antiangiogenic drugs versus chemotherapy in glioblastomapatients from January 2006 to January 2016 in MEDLINE, WEB of SCIENCE, ASCO, ESMO and SNO databases. RESULTS: fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR=1.24, p=0.056). Bevacizumab did not improve overall survival. Twelve trials (4113 patients) were analyzed for progression-free survival. Among antiangiogenic drugs, only bevacizumab demonstrated an improvement of progression-free survival (HR=0.63, p<0.001), both alone (HR=0.60, p=0.003) or in combination to chemotherapy (HR=0.63; p<0.001), both as first-line treatment (HR=0.70, p<0.001) or in recurrent disease (HR=0.52, p<0.001). CONCLUSIONS: antiangiogenic drugs did not improve overall survival in glioblastomapatients, either as first or second-line treatment, and either as single agent or in combination with chemotherapy. Among antiangiogenic drugs, only bevacizumab improved progression-free survival regardless of treatment line, both as single agent or in combination with chemotherapy.
Authors: Vinay K Puduvalli; Jing Wu; Ying Yuan; Terri S Armstrong; Elizabeth Vera; Jimin Wu; Jihong Xu; Pierre Giglio; Howard Colman; Tobias Walbert; Jeffrey Raizer; Morris D Groves; David Tran; Fabio Iwamoto; Nicholas Avgeropoulos; Nina Paleologos; Karen Fink; David Peereboom; Marc Chamberlain; Ryan Merrell; Marta Penas Prado; W K Alfred Yung; Mark R Gilbert Journal: Neuro Oncol Date: 2020-10-14 Impact factor: 12.300
Authors: Alba A Brandes; Miguel Gil-Gil; Frank Saran; Antoine F Carpentier; Anna K Nowak; Warren Mason; Vittorina Zagonel; François Dubois; Gaetano Finocchiaro; George Fountzilas; Dana Michaela Cernea; Oliver Chinot; Rodica Anghel; Francois Ghiringhelli; Patrick Beauchesne; Giuseppe Lombardi; Enrico Franceschi; Martina Makrutzki; Chiedzo Mpofu; Hans-Joerg Urban; Josef Pichler Journal: Oncologist Date: 2018-09-28
Authors: Dipongkor Saha; Hiroaki Wakimoto; Cole W Peters; Slawomir J Antoszczyk; Samuel D Rabkin; Robert L Martuza Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531
Authors: E George; E Flagg; K Chang; H X Bai; H J Aerts; M Vallières; D A Reardon; R Y Huang Journal: AJNR Am J Neuroradiol Date: 2022-04-28 Impact factor: 3.825
Authors: Malaka Ameratunga; Nick Pavlakis; Helen Wheeler; Robin Grant; John Simes; Mustafa Khasraw Journal: Cochrane Database Syst Rev Date: 2018-11-22